Edgewise Therapeutics Swings to Q3 2026 Net Profit of $1.17 Billion

Edgewise Therapeutics reported net income of $1.17 billion, or $9.65 per diluted share, for the third quarter of 2026, compared with a $40.7 million net loss, or a $0.39 loss per share, a year earlier. Results included a $1.35 billion gain from the sale of sevasemten and the muscular dystrophy prog…